web analytics
10.3 C
Munich
Monday, April 19, 2021

The Exciting Story of BioElectronics Corp. (OTCPINK: BIEL)

BioElectronics Corp. (OTCPINK: BIEL) is an exciting stock with a long history of big moves running from triple zero lows to highs of $0.005 earlier this year. The stock is a volume leader and has quickly attracted a growing shareholder base who see big things happening here.

BIEL operates in the booming chronic pain market which is larger than diabetes, heart disease, and cancer combined, with 20% of adults globally suffering from chronic pain. ActiPatch addresses the unmet need for 1.5 billion worldwide chronic pain sufferers. The Company’s medical devices modulate the body’s nerve activity to dampen the pain perception, which reduces drug use.

BioElectronics Corp. (OTCPINK: BIEL) bills itself as is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. BIEL innovative pulsed shortwave therapy technology (PSWT) uses low power pulsed electromagnetic fields regulate electrical activity of the nervous system. The neuromodulation basis of PSWT presents significant opportunities for BioElectronics to develop optimized technology for diabetic neuropathy, postoperative surgery, chronic wounds, and other applications.

BioElectronics OTC product line includes ActiPatch® Musculoskeletal Pain Therapy, Allay® Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy, and RecoveryRx® Post-operative and Chronic Wounds Therapy. The US FDA clearance is for the company’s flagship product the ActiPatch® Musculoskeletal Pain Therapy, developed to relieve chronic pain. ActiPatch is a drug-free, wearable nonprescription medical device that provides 720-hours (90, 8-hour treatments) of on/off therapy. Most users obtain relief with only 8 hours per day of use, so the device will generally last several months, depending on use. The Company is aggressively pursuing US FDA over-the-counter market clearance to access the United States market.

The Companies technology offers significant opportunities in menstrual pain, heel pain, migraine headaches, diabetic neuropathy, postoperative surgery, chronic wounds, bone growth stimulation,and other applications. In February 2017, BioElectronics announced that it received over-the-counter use market clearance from the US FDA for ActiPatch® for the adjunctive treatment of musculoskeletal pain related to plantar fasciitis of the heel, and osteoarthritis of the knee.

To Find out the inside Scoop on BIEL Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BioElectronics has filed on July 11, 2018 a 510(k) submission to obtain expanded market clearance for over-the-counter (OTC) treatment of musculoskeletal pain. This would make ActiPatch available as a drug-free, safe, pain relief option for the 126 million Americans who are suffering with some form of musculoskeletal pain. While ActiPatch is already FDA cleared for treatment of pain from knee osteoarthritis and plantar fasciitis, expanded market clearance would allow additional products for the back, neck and hip.

The last press release from the Company was on October 4, BIEL announced the publication of an article in the October 2018 edition of the European Biopharmaceutical Review. Titled “Effective Electroceuticals,” the article provides insights into how electroceuticals (devices that provide electrical therapy) are set to revolutionize chronic pain management in the 21st century.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $36 million market valuation BIEL did $685,000 in sales for the 3 months ended June 30, 2018. The Company has little cash on hand with over $6 million in current liabilities. BIEL is an exciting story in small caps; the Company is already selling its flagship, the ActiPatch and recently filed a 510(k) with the FDA to obtain expanded market clearance for the over-the-counter (OTC) treatment of musculoskeletal pain. BIEL has a large shareholder base who believe in the Company and their products and their ability to disrupt a billion-dollar market. There is huge demand for BIEL here, more than most penny stocks could dream of, if they can reach an agreement with debt holders big things could happen here. We will be updating on BIEL when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BIEL.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in  BIEL either long or short and we have not been compensated for this article

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.